WHAT IS CLAIMED IS:

1. A composition of therapeutic cells for allogeneic infusion into a recipient, the composition comprising a population of human T-Cells including a population of T-Vehicles, wherein the T-Vehicles comprise a population of antigen specific human T cells which has a native T cell receptor that recognizes a non-human antigen, and the T-Vehicles being genetically modified to produce a cytokine;
wherein when the composition of therapeutic cells is administered to the recipient, the T-Vehicles migrate to a site of inflammation and deliver the cytokine to the site of inflammation.

2. The T-Vehicles of claim 1, being genetically modified to produce IL7.

3. The T-Vehicles of any one of claims 1 to 2, having a native antigen receptor that only recognizes a single epitope of the non-human antigen.

4. The T-Vehicles of any one of claims 1 to 2, wherein the non-human antigen is from a virus.

5. The composition of therapeutic cells of Claim 1, wherein said population of human T cells are obtained by seeding PBMCs and medium into a device that includes a growth surface comprised of gas permeable material at a medium volume to growth surface area ratio of at least 2 mL/cm^2 and stimulating the PBMCs with a viral antigen to activate the growth of T cells that have native antigen specificity to the viral antigen.

6. The composition of therapeutic cells of Claim 1 wherein the recipient is a cancer patient.

7. The T-Vehicles of Claim 1 being genetically modified to produce IL2.